AMAG Pharmaceuticals announced that the FDA has approved its application to broaden the existing label for Feraheme (ferumoxytol injection) beyond...
AMAG Pharmaceuticals announced that the FDA has accepted its submission to broaden the existing label for Feraheme (ferumoxytol) to include...
AMAG Pharmaceuticals, Inc. announced positive top-line results from a Phase III randomized, double-blind, non-inferiority clinical trial evaluating Feraheme (ferumoxytol) compared...
Amag Pharmaceuticals, Inc. announced that the FDA has issued a Complete Response Letter for the supplemental new drug application (sNDA)...